UNSPSC 51151505: Tropatepine hydrochlorate

This classification denotes a tropane and dibenzothiepin with the molecular formula C22H23NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C27HY5RFU5, chemically known as 8-azabicyclo(3.2.1)octane, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-8-methyl- but generally known as tropatepine, which bears US NIH Compound Identifier 72148. European Medicines Agency schedules Tropatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11340MIG.

UNSPSC 51151505 Tropatepine hydrochlorate is a Commodity code that does not reflect the actual work being solicited under it in recent state and local procurement activity. The source contains two recent opportunities tagged to this code: Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI regarding a direct-to-manufacturer prescription program. Neither solicitation involves tropatepine hydrochlorate or pharmaceuticals matching the code's nominal scope. The Seminole County IFB explicitly seeks naloxone units and deactivation equipment for community health initiatives, while the Texas HHS RFI explores pharmacy benefit program infrastructure and contracting models without naming specific drug products. The mismatch between the code designation and the actual procurement suggests either a classification error in the source data or that the code is being used as a catch-all for pharmaceutical and health-related commodities that do not fit the code's precise definition.

Issuing bodies soliciting under this code include county health departments and state health and human services agencies. Geographic activity appears limited to Florida and Texas based on recent postings. The Seminole County IFB, posted June 30, 2026, with a response deadline of July 26, 2023, requires quarterly deliveries of naloxone and drug deactivation systems with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI, posted April 3, 2026, with the same response deadline, sought vendor capabilities for direct pharmaceutical procurement arrangements. Neither opportunity specifies explicit set-aside designations. Without additional opportunities clearly aligned to the tropatepine hydrochlorate code scope, activity under this code shows little relevant recent momentum for vendors pursuing pharmaceutical commodity sales to state and local buyers.